RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Update

RenovoRx, Inc. (NASDAQ:RNXT) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 91,900 shares, a decrease of 19.6% from the September 30th total of 114,300 shares. Based on an average daily volume of 32,400 shares, the short-interest ratio is presently 2.8 days. Approximately 0.4% of the company’s shares are sold short.

RenovoRx Trading Down 3.2 %

NASDAQ:RNXT traded down $0.03 during mid-day trading on Friday, reaching $0.90. The company’s stock had a trading volume of 12,596 shares, compared to its average volume of 45,080. The stock has a market cap of $21.56 million, a P/E ratio of -1.25 and a beta of 0.99. The firm’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.15. RenovoRx has a 12-month low of $0.53 and a 12-month high of $2.35.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter. Analysts predict that RenovoRx will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets lifted their price objective on shares of RenovoRx from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Thursday, September 12th.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.